<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709173</url>
  </required_header>
  <id_info>
    <org_study_id>C-000918-3</org_study_id>
    <nct_id>NCT03709173</nct_id>
  </id_info>
  <brief_title>FuRST 2.0 Cognitive Pre-testing - Round 2</brief_title>
  <official_title>FuRST 2.0: Cognitive Pre-testing for a New Functional Rating Scale for Use in Huntington's Disease - Round 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHDI Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Glenn T. Stebbins (Rush University Medical Center )</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Nancy LaPelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHDI Foundation, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single, cross-sectional cognitive interview of FuRST 2.0, functional rating&#xD;
      scale, administered to forty Huntington's Disease Gene Expansion Carriers (HDGECs) and&#xD;
      potentially, their companions (the companion's participation is optional in this study). The&#xD;
      scale will be tested as a patient reported outcome (PRO) in that the information will come&#xD;
      directly from the HDGEC participant or the HDGEC participant together with his/her companion&#xD;
      through self-report. The purpose is to identify real or potential comprehension or usage&#xD;
      problems with scale items, response options, instructions and disclaimer statement, which are&#xD;
      all components of the FuRST 2.0 scale. Through a structured cognitive interview with the&#xD;
      HDGEC participants or the HDGEC participants together with their companions, followed by&#xD;
      qualitative analysis, the final phrasing of the individual scale items, response options,&#xD;
      instructions and disclaimer statement for the scale will be generated. Depending on the&#xD;
      results of this study, an additional round of cognitive pre-testing may be required in a&#xD;
      separate study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Actual">October 25, 2019</completion_date>
  <primary_completion_date type="Actual">October 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participant's comprehension of the FuRST 2.0 rating scale measured by qualitative analysis.</measure>
    <time_frame>7 months</time_frame>
    <description>The primary assessment will use qualitative analysis of the cognitive interview to determine the usability of the FuRST 2.0 scale in the HD population.&#xD;
Note: The instructions, items, response options and disclaimer statement are all part of the FuRST 2.0 scale.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">52</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Premanifest HDGEC participants</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Early-manifest HDGEC participants</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Companions of Premanifest HDGEC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Companions of Early-manifest</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>FuRST 2.0</intervention_name>
    <description>Round 2 of cognitive pre-testing for a new functional rating scale</description>
    <arm_group_label>Companions of Early-manifest</arm_group_label>
    <arm_group_label>Companions of Premanifest HDGEC</arm_group_label>
    <arm_group_label>Early-manifest HDGEC participants</arm_group_label>
    <arm_group_label>Premanifest HDGEC participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        An HDGEC: Premanifest and early-manifest HDGEC who is also a participant in Enroll-HD and&#xD;
        meets the protocol selection criteria for the HDGEC. HDGEC participants will be recruited&#xD;
        from English speaking Enroll-HD sites.&#xD;
&#xD;
        A Companion: A person who, in his/her opinion, has sufficient interaction and knowledge of&#xD;
        the HDGEC participant's capabilities and daily activities, is acceptable to the HDGEC&#xD;
        participant and the site principal investigator (site PI) or site PI's designee and meets&#xD;
        the protocol selection criteria for the companion. The companion's participation is&#xD;
        optional in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Premanifest HDGECs:&#xD;
&#xD;
          -  Identified as an active participant in Enroll-HD (participants who have completed&#xD;
             their last onsite Enroll-HD visit within approximately 15 months)&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Fluent in English and had his/her primary education in English&#xD;
&#xD;
          -  Able and willing to provide critical feedback (per site PI or site PI's designee&#xD;
             discretion)&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Cytosine, Adenine, Guanine (CAG) length ≥ 40&#xD;
&#xD;
          -  Disease burden score (DBS) ≥ 250&#xD;
&#xD;
          -  Diagnostic confidence level (DCL) ≤ 3&#xD;
&#xD;
        Inclusion Criteria for Early-manifest HDGECs:&#xD;
&#xD;
          -  Identified as an active participant in Enroll-HD (participants who have completed&#xD;
             their last onsite Enroll-HD visit within approximately 15 months)&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Fluent in English and had his/her primary education in English&#xD;
&#xD;
          -  Able and willing to provide critical feedback (per site PI or site PI's designee&#xD;
             discretion)&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  CAG length ≥ 36&#xD;
&#xD;
          -  DCL= 4&#xD;
&#xD;
          -  Total Functional Capacity (TFC) ≥11&#xD;
&#xD;
        Inclusion Criteria for a Companion of an HDGEC&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Fluent in English and had his/her primary education in English&#xD;
&#xD;
          -  In his/her opinion, has sufficient interaction and knowledge of the HDGEC&#xD;
             participant's capabilities and daily activities&#xD;
&#xD;
          -  Is acceptable to the HDGEC participant and the site PI or site PI's designee&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria for an HDGEC/a companion of HDGEC:&#xD;
&#xD;
          -  Significant cognitive or any other impairment sufficient to interfere with study&#xD;
             associated tasks as judged by the site PI or the site PI's designee&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center, P.C.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hereditary Neurological Disease Centre, Inc.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Movement Disorders (Neuropharm Consulting)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

